ChiCTR2200059549 版本V1.3 版本创建时间2023/02/12 22:45:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200059549 

最近更新日期:

Date of Last Refreshed on:

2023-02-12 22:43:37 

注册时间:

Date of Registration:

2022-05-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经皮神经电刺激对儿童功能性便秘效果观察及机制初探

Public title:

Effect and mechanism of percutaneous electrical nerve stimulation on functional constipation in children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经皮神经电刺激对儿童功能性便秘效果观察及机制初探

Scientific title:

Effect and mechanism of percutaneous electrical nerve stimulation on functional constipation in children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郭飘 

研究负责人:

朱丹荣 

Applicant:

Guo Piao 

Study leader:

Zhu Danrong 

申请注册联系人电话:

Applicant telephone:

+86 18895686913

研究负责人电话:

Study leader's
telephone:

+86 13032552597

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1782425747@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhudanrong@njmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区中山北路262号

研究负责人通讯地址:

江苏省南京市鼓楼区中山北路262号

Applicant address:

262 Zhongshan Road North, Gulou District, Nanjing, Jiangsu

Study leader's address:

262 Zhongshan Road North, Gulou District, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Nanjing Medical University

研究负责人所在单位:

南京医科大学第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Nanjing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

YY2021-0041

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

伊犁哈萨克自治州友谊医院伦理委员会

Name of the ethic committee:

Ethics Committee of Friendship Hospital of lli Kazak Autonomous Prefecture

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-26 00:00:00

伦理委员会联系人:

张闻歌

Contact Name of the ethic committee:

Zhang Wen'ge

伦理委员会联系地址:

新疆伊犁哈萨克自治州伊宁市斯大林街92号

Contact Address of the ethic committee:

92 Sidalin Street, Yi'ning City, Ili Kazak Autonomous Prefecture, Xinjiang Uygur Autonomous Region

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Nanjing Medical University

研究实施负责(组长)单位地址:

江苏省南京市鼓楼区中山北路262号

Primary sponsor's address:

262 Zhongshan Road North, Gulou District, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京医科大学第二附属医院

具体地址:

鼓楼区中山北路262号

Institution
hospital:

The Second Affiliated Hospital of Nanjing Medical University

Address:

262 Zhongshan Road North, Gulou District

国家:

中国

省(直辖市):

新疆维吾尔自治区

市(区县):

伊犁哈萨克自治州

Country:

China

Province:

Xinjiang Uygur Autonomous

City:

Ili Kazak Autonomous Prefecture

单位(医院):

伊犁州友谊医院

具体地址:

伊宁市斯大林街92号

Institution
hospital:

Yili Friendship Hospital

Address:

92 Sidalin Street, Yi'ning City

经费或物资来源:

申请自治州财政拨款

Source(s) of funding:

Apply for financial appropriation of Autonomous Prefecture

研究疾病:

儿童功能性便秘  

Target disease:

Functional constipation inchildren

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.探讨经皮神经电刺激(TENS)治疗儿童功能性便秘的安全性及有效性; 2.探讨TENS在我国儿童功能性便秘(functional constipation ,FC)的作用及是否通过多种机制来治疗儿童功能性便秘。  

Objectives of Study:

1. To investigate the safety and effectiveness of transcutaneous electrical nerve stimulation (TENS) in the treatment of children with functional constipation; 2. To explore the role of TENS in Chinese children functional constipation and whether multiple mechanisms are used to treat functional constipation in children.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄4-14周岁;
2.符合罗马IV功能性便秘诊断标准;
3.排除食物过敏引起便秘者(如牛奶、鸡蛋等食物);
4.能坚持参加试验随访者;
5. >4岁的儿童罗马IV功能性便秘诊断标准符合下列2项或以上,且不符合肠易激综合症的诊断标准,症状每周至少1次,持续2个月以上:
(1)每周排便≦2次;
(2)每周至少有1次大便失禁;
(3)有大量粪便潴留史或有与粪潴留有关的姿势;
(4)排便困难或疼痛者;
(5)直肠中有巨大的粪块;
(6)排出的粪便粗大以至于堵塞下水道。

Inclusion criteria

1. Aged 4-14 years;
2. Meet the diagnostic criteria of Rome IV functional constipation;
3. Eliminate constipation caused by food allergy (such as milk, eggs and other foods);
4. Can persist in participating in the experiment interviewees;
5. Children >4 years of age meet two or more of the following diagnostic criteria for Rome IV functional constipation, and do not meet the diagnostic criteria for irritable bowel syndrome, and symptoms occur at least once a week for more than 2 months:
(1) No more than 2 bowel movements per week;
(2) Fecal incontinence at least once a week;
(3) Have a history of fecal retention or have a posture related to fecal retention;
(4) Difficult or painful defecation;
(5) Large fecal mass in the rectum;
(6) The excrement is so thick that it clogs the sewer.

排除标准:

1.拒绝签署知情同意;
2.近期服用促运动药、抗胆碱能药或多巴胺能药物;
3.有腹部手术史;
4.患有糖尿病或其他代谢性疾病;
5.肝胆疾病患者;
6.设备部件过敏;
7.拒绝留取粪便和血液样品的患者。

Exclusion criteria:

1. Refuse to sign informed consent;
2. Recently taking motor promoting drugs, anticholinergic drugs or dopaminergic drugs;
3. History of abdominal surgery;
4. Diabetes or other metabolic diseases;
5. Patients with liver and gallbladder diseases;
6. Allergy to equipment components;
7. Patients who refuse to take stool and blood samples.

研究实施时间:

Study execute time:

From 2022-04-30 00:00:00 To 2023-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-30 00:00:00 To 2023-05-31 00:00:00

干预措施:

Interventions:

组别:

乳果糖组

样本量:

30

Group:

Lactulose group

Sample size:

干预措施:

口服乳果糖

干预措施代码:

Intervention:

Oral lactulose

Intervention code:

组别:

TNES组

样本量:

30

Group:

TNES group

Sample size:

干预措施:

经皮电刺激

干预措施代码:

Intervention:

Percutaneous electrical stimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京医科大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Nanjing Medical University

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

新疆维吾尔自治区 

市(区县):

伊犁哈萨克自治州 

Country:

China

Province:

Xinjiang Uygur Autonomous

City:

Ili Kazak Autonomous Prefecture

单位(医院):

伊犁州友谊医院 

单位级别:

三级甲等 

Institution
hospital:

Yili Friendship Hospital

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

粪便肠道菌群

指标类型:

主要指标

Outcome:

Fecal intestinal flora

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率变异性(HRV)

指标类型:

次要指标

Outcome:

Heart rate variability (HRV)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

韦克斯纳便秘得分(WCS)

指标类型:

次要指标

Outcome:

Wexner Constipation Score (WCS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件和不良反应发生率

指标类型:

副作用指标

Outcome:

Incidence of adverse events and adverse reactions

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗有效率

指标类型:

主要指标

Outcome:

Therapeutic response rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃动素

指标类型:

主要指标

Outcome:

Gastric dynamic element

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-6

指标类型:

主要指标

Outcome:

IL-6

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-12

指标类型:

主要指标

Outcome:

IL-12

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人新喋呤

指标类型:

主要指标

Outcome:

New people with poison

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Bristol 粪便性状

指标类型:

次要指标

Outcome:

Bristol Stool Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 4 years
最大 Max age 14 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由独立统计师使用SAS9.4统计分析软件,使用区组随机化方法产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequences were generated by independent statisticians using SAS9.4 statistical analysis software using block randomization.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在实验结果完成发表时公开原始数据,可与主要研究者直接联系获取原始数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish the original data when the results are published, and contact the principal investigator directly to obtain the original data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

原始的数据记录及病例记录表,纸质版由实验负责人保存;电子版采用EXCEL及SPSS格式进行保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All of the original data records and case records, the paper version materials was preserved by experimental operator, and the electronic version records was saved by using EXCEL and SPSS software.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-05-04 02:17:06